Entos Pharmaceuticals Awarded $4 Million USD in Funding from the California Institute for Regenerative Medicine (CIRM) for its Congenital Generalized Lipodystrophy Program

Entos Pharmaceuticals Awarded $4 Million USD in Funding from the California Institute for Regenerative Medicine (CIRM) for its Congenital Generalized Lipodystrophy Program

SAN DIEGO -- Entos® Pharmaceuticals (Entos), a clinical-stage genetic medicines company committed to using its Fusogenix™ PLV™ technology to develop cures and improve the lives of patients and their families, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M USD grant. The funds will support the completion of IND-enabling activities for the development of ENTLEP001, a durable genetic med…